ArticleThe Journal of urology2022
Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
Article in The Journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis.Annals of medicine · 2025Pooled it
- Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.European urology · 2023Trial
- Diuretic-Enhanced Dual-Phase F-18 FDG PET/CT: A New Window Into Muscle-Invasive Bladder Cancer.World journal of nuclear medicine · 2026Article
- The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Review
- Overexpression ofDiagnostics (Basel, Switzerland) · 2025Article
- Constructing a bladder cancer prognostic model related to exosome using machine learning and identifying THBS1 as a potential target.Cancer cell international · 2025Article
- Clinically lymph node-positive urothelial bladder cancer treated with upfront radical cystectomy: Diagnostic accuracy of MRI and long-term oncologic outcomes.Asian journal of urology · 2025Article
- Urinary exosomal lnc-TAF12-2:1 promotes bladder cancer progression through the miR-7847-3p/ASB12 regulatory axis.Genes & diseases · 2025Article
- Comprehensive analysis of RNA methylation-related genes to identify molecular cluster for predicting prognosis and immune profiles in bladder cancer.Scientific reports · 2025Article
- Article
- The role of radical cystectomy and lymphadenectomy in the management of bladder cancer with clinically positive lymph node involvement.Current opinion in urology · 2025Review
- A nomogram based on preoperative NLR predicts distant metastasis of urothelial carcinoma of the bladder.Cancer biomarkers : section A of Disease markers · 2024Article
- Temporal Trends in Urinary Diversion among Patients Undergoing Radical Cystectomy Between 1986 and 2022: Experience at the University Medical Center Mainz with 2224 Cases.Annals of surgical oncology · 2024Article
- ASO Author Reflections: Temporal Trends in Urinary Diversion in Radical Cystectomies from Europe's Largest Monocentric Cohort with 2224 Cases Over 36 Years.Annals of surgical oncology · 2024Article
- Radical cystectomy in patients aged < 80 years versus ≥ 80 years: analysis of preoperative geriatric assessment scores in predicting postoperative morbidity and mortality.World journal of urology · 2024Article
- The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature.Journal of clinical medicine · 2024Review
- Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases.Nature reviews. Urology · 2024Review
- Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.JCO precision oncology · 2024Article
- The impact of chemotherapy-naïve open radical cystectomy delay and perioperative transfusion on the recurrence-free survival: A perioperative parameters-based nomogram.Asian journal of urology · 2024Article
- Quantitative differentiation of non-invasive bladder urothelial carcinoma and inverted papilloma based on CT urography.BMC urology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeThere are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer. MATERIALS AND
methodsEvolution of modern bladder cancer management and its impact on outcomes was analyzed using a longitudinal cohort of 3,347 patients who underwent RC at an academic center between 1971 and 2018. Outcomes included recurrence-free survival (RFS) and overall survival (OS). Associations were assessed using univariable and multivariable models.
resultsIn all, 70.9% of cases underwent open RC in the last decade, although trend for robot-assisted RC rose since 2009. While lymphadenectomy template remained consistent, nodal submission changed to anatomical packets in 2002 with increase in yield (p <0.001). Neoadjuvant chemotherapy (NAC) use increased with time with concomitant decrease in adjuvant chemotherapy; this was notable in the last decade (p <0.001) and coincided with improved pT0N0M0 rate (p=0.013). Median 5-year RFS and OS probabilities were 65% and 55%, respectively. Advanced stage, NAC, delay to RC, lymphovascular invasion and positive margins were associated with worse RFS (all, multivariable p <0.001). RFS remained stable over time (p=0.73) but OS improved (5-year probability, 1990-1999 51%, 2010-2018 62%; p=0.019). Among patients with extravesical and/or node-positive disease, those who received NAC had worse outcomes than those who directly underwent RC (p ≤0.001).
conclusionsDespite perioperative and surgical advances, and improved pT0N0M0 rates, there has been no overall change in RFS trend following RC, although OS rates have improved. While patients who are downstaged with NAC derive great benefit, our real-world experience highlights the importance of preemptively identifying NAC nonresponders who may have worse post-RC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.